John Abraham: Telomere Biology Disorders – From Bench to Bedside
John Abraham, Assistant Professor at Christian Medical College and Hospital, shared a post on Linkedin about a recent article by Madeline Franke et al., published in Haematologica, adding:
“Telomere Biology Disorders (TBD): From Bench to Bedside
Recently revisited an excellent review in Haematologica (March 2026) by Madeline Franke et al., focusing on the diagnosis and management of adult telomere biology disorders.
Here are key takeaways
Core concept
TBD represent inherited defects in telomere maintenance leading to short telomeres, genomic instability, and multisystem disease.
Biology simplified
Telomeres (TTAGGG repeats) plus telomerase plus shelterin complex
- Maintain chromosomal integrity
- Progressive shortening triggers cell senescence and malignancy risk
Classification
- Short telomere syndromes (TBD) – organ failure, aging phenotype
- Long telomere syndromes (CPLT) – paradoxical increased cancer risk
Genetics
Mutations in key genes (TERT, TERC, DKC1, RTEL1, TINF2)
- Affect telomerase activity, trafficking, or telomere protection
Clinical spectrum (Adults)
- Bone marrow failure
- Interstitial lung disease (often the presenting feature)
- Liver fibrosis/portal hypertension
- Premature aging features
Cancer and hematology Risk
- MDS (approximately 500 fold increase risk)
- AML (20–70 fold increase risk)
- Clonal hematopoiesis plays a central role
Adaptive vs maladaptive clones (TP53, U2AF1)
Diagnosis
- Flow-FISH is clinical gold standard
- Genetic testing essential
- Up to 40% may lack identifiable mutations
Unique concepts
- Genetic anticipation – earlier, more severe disease
- Phenocopying – TBD phenotype without mutation
Management
- Androgens (e.g., danazol) – potential telomere elongation (mixed evidence)
- Transplant remains definitive (HSCT / lung / liver)
Requires reduced-intensity conditioning
Surveillance
- CBC plus marrow monitoring
- Cancer screening (H and N, skin, anogenital)
- Pulmonary and liver evaluation
Multidisciplinary care is key
Future directions
- Gene editing (ZSCAN4, TINF2)
- Telomerase-targeted therapies
Early-phase clinical trials underway
Take-home
Think TBD in:
- Unexplained cytopenias plus ILD plus family history
- Early greying plus marrow failure
- ‘Atypical’ MDS/AML in younger patients
Early recognition – better outcomes.”
Title: Diagnosis and management of adult telomere biology disorders
Authors: Madeline Franke, Alejandro Ferrer, Mrinal M. Patnaik
Read the Full Article on Haematologica
Stay updated with Hemostasis Today.
-
Oct 14, 2026, 20:36How Does Inflammation Reshape Red Blood Cell Production? – ASH
-
Oct 14, 2026, 20:30Marilena Vrana: Putting Faces to the Chain – Donors and Patients Connect in Milan for IPAW 2026
-
Oct 14, 2026, 20:25Asim Alam: Hillsborough County and Partners Demonstrate Drone-Based Emergency Blood Delivery
-
Oct 14, 2026, 20:19Zahid Khanzada: 3rd Position in the Hematology Quiz at PCUH
-
Oct 14, 2026, 20:14Samiul Bashir: The 47th Recognized System in Transfusion Medicine
-
Oct 14, 2026, 20:06Mavis Agnes Kisakye: Petition Advocating for Enhanced Haemophilia Care Presented to EALA Parliament
-
Oct 14, 2026, 20:03Sheharyar Raza: What Are Ways AI and ML Are Impacting How We Collect and Transfuse Blood?
-
Oct 14, 2026, 19:58Alessandro Lucchesi: Three Minutes of RiseMPN 2025
-
Oct 14, 2026, 19:55Talha Waseem: HbA1c – What Does Its Name Actually Mean?